Krystal Biotech Inc Phase 1/2 Clinical Trial of KB103 Final Update Call Transcript
Good morning, and welcome to the Krystal Biotech Phase I/II clinical data presentation. The purpose of today's presentation is to walk through the data at a wound level and provide more clarity on the press release that we issued this morning.
Slide 2, please. Before I begin, please take a minute to read the forward-looking statement. I need to remind everyone that remarks made during the call may contain forward-looking statements that involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in these statements is based on current expectations and is subject to change, and actual results may differ materially from forward-looking statements.
Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainty. Detailed information regarding factors that may cause actual results to differ materially from
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |